CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease

Status: Recruiting

Eligibility Criteria

Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers

Inclusion Criteria:

- 18 years to 130 years old - confirmed ER+/HER2- early-stage resected invasive breast cancer - may have received up to 12 weeks of endocrine therapy - start the study within 12 months of definitive breast surgery - strenuous activity may be restricted but able to walk and do light or sedentary work e.g., light house work, office work - see link to clinicaltrials.gov for complete inclusion and exclusion criteria

Exclusion Criteria:

- inoperable locally advanced or metastatic breast cancer - history of any other cancer in the past 5 years that required treatment - women who are pregnant or breast feeding

Conditions & Interventions

Conditions:
Cancer
Keywords:
Breast Cancer

More Information

Description: This is study to determine if a new drug, camizestrant, improves outcomes compared to usual adjuvant endocrine therapy for people who have ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence. People who have completed initial therapy (with or without chemotherapy) are eligible for the trial. Treatment is planned to continue for 7 years.
Study Contact: Kristen Nelson - knelso65@fairview.org
Principal Investigator: Kiran Lassi
Phase: PHASE3
IRB Number: MMCORC080